Up next

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More 

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette.  

General 
* Thermo Fisher to Acquire Clario Holdings for $8.8 Bn
* Lonza To Acquire Redberry SAS 
* Alcami To Expand Lab Services 
Chemicals/Chemical API Manufacturing 
* Sai Life Sciences Breaks Ground on New CMC Process R&D Center  
* Piramal Pharma, IntoCell Partner for ADC Development 
Biologics Manufacturing 
* Lotte Biologics, SK pharmteco Partner To Expand ADC Capabilities 
Formulation Development/Drug Product Manufacturing 
* Hovione Completes Initial $100-M Investment Cycle in US Operations 
* Roquette Opens Innovation Center in Brazil 
Appointments 
* BioCina Names New CEO 

General 

Thermo Fisher to Acquire Clario Holdings for $8.8 Bn 
Thermo Fisher Scientific has agreed to acquire Clario Holdings, a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding, and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance. Upon close, Clario will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment. 

Clario integrates clinical trial endpoint data from devices, sites, and patients to pharma and biotech customers to collect, manage, and analyze clinical evidence digitally across all phases of drug development. Clario provides electronic clinical outcome assessments, medical imaging, cardiac solutions, respiratory assessments, and wearable data capture technologies designed to ensure the scientific integrity and regulatory compliance of clinical trial outcomes. Clario operates globally and has approximately 4,000 employees. For the full year 2025, Clario is expected to generate approximately $1.25 billion of revenue. 

The transaction is expected to be completed by the middle of 2026, subject to customary closing conditions and regulatory approvals. In addition to the initial cash purchase price at closing, Thermo Fisher has agreed to pay $125 million in January 2027. Thermo Fisher has also agreed to pay up to $400 million of earn-out payments based on the performance of the business in 2026 and 2027. 

Source: Thermo Fisher Scientific  

Lonza To Acquire Redberry SAS 
Lonza has agreed to acquire Redberry SAS, a company specializing in rapid microbiology testing solutions using solid-phase cytometry technology. 

In April 2025, Redberry announced the successful validation of its Red One rapid sterility testing method that delivers results in four days. This solution offers a GMP-compliant alternative to traditional sterility testing, which typically requires a minimum incubation time of 14 days, according to information from Lonza. 

The transaction is expected to close in the fourth quarter of 2025, subject to closing conditions. 

Source: Lonza 

Alcami To Expand Lab Services 
Alcami, a CDMO of drug products and provider of analytical testing services, has announced the expansion of its laboratory services at its facility in Durham, North Carolina. 

The 20,000-square-foot expansion, which began in the fourth quarter of 2025 and is expected to be finalized in 2026, will strengthen Alcami’s analytical capabilities in support of biologics, peptides, oligonucleotides, antibody-drug conjugates, and cell- and gene-therapy drug substances and drug products. The site will feature expanded capacity for method establishment, release and stability testing, as well as biologics characterization using instrumentation in bioseparation, mass spectrometry, electrophoresis, and bioassay methodologies.  

Source: Alcami 

Chemicals/Chemical API Manufacturing 

Sai Life Sciences Breaks Ground on New CMC Process R&D Center  
Sai Life Sciences, a contract research organization and a CDMO of small-molecule active pharmaceutical ingredients (APIs) and intermediates, has announced the groundbreaking for a new CMC Process R&D Center at its campus in Hyderabad, India. Scheduled for completion by September 2026, the facility will double the company’s process R&D capacity while adding new capabilities in peptide development, oligo intermediates & linkers development, formulation development, and early-phase clinical supplies. 

Highlights of the upcoming facility: 

  • Total built-up area of 100,000 square feet (9,300 square meters) over five floors; 
  • 140 process chemistry fume hoods with an integrated satellite analytical lab; 
  • Dedicated laboratories for peptides and oligo intermediates & linkers; 
  • 25,000 sq. ft. centralized analytical laboratory; 
  • New chemical entity formulation development and early-phase clinical supply capabilities; 
  • Kilo lab for early clinical manufacturing; 
  • Containment down to OEL 4 (1 µg/m³); and 
  • Designed as a “Green Building.” 

Source: Sai life Sciences 

Piramal Pharma, IntoCell Partner for ADC Development 
Piramal Pharma Solutions, a CDMO of active pharmaceutical ingredients and drug products, has signed a Memorandum of Understanding for a strategic partnership to explore potential collaboration opportunities in antibody-drug conjugate (ADC) development with IntoCell, a biotechnology company specializing in ADC linker and payload platform technologies.  

Under the agreement, IntoCell will explore licensing opportunities for its drug-linker technologies with Piramal’s clients. In exchange, Piramal will offer contract research, development, and manufacturing of bioconjugates, including ADCs, to IntoCell and its client base. 

Source: Piramal Pharma Solutions 

Biologics Manufacturing 

Lotte Biologics, SK pharmteco Partner To Expand ADC Capabilities 
SK pharmteco, a CDMO of small-molecule active pharmaceutical ingredients (APIs) and cell and gene therapies, and Lotte Biologics, a CDMO of biologics, have signed a Letter of Intent for a strategic collaboration in antibody-drug conjugates (ADCs). Through thie collaboration, the two companies will jointly investigate providing integrated, one-stop CDMO services to global clients for ADCs that span from development to commercial manufacturing. 

Lotte will utilize its cGMP manufacturing capabilities at its Syracuse Bio Campus in the US to deliver bioconjugation and drug-substance manufacturing services while SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process. 

Source: SK pharmteco 

Formulation Development/Drug Product Manufacturing 

Hovione Completes Initial $100-M Investment Cycle in US Operations 
Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.  

The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026. 

As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities. 

Source: Hovione 

Roquette Opens Innovation Center in Brazil 
Roquette, a manufacturer of excipients and plant-based ingredients, has opened a new innovation center in São Paulo, Brazil. The facility represents a multi-million-dollar investment and includes laboratory and training rooms for customers. Additionally, it will enable scientific experts to leverage advanced tools, technologies, and expertise to deliver tailored solutions to customers. 

Source: Roquette 

Appointments 

BioCina Names New CEO 
BioCina, an Adelaide, Australia-based CDMO, has announced that Dr. Thomas Broudy, currently Operating Partner of Bridgewest Group’s life sciences portfolio, has been appointed as CEO to lead the company’s growth of its biologic drug-substance and sterile drug-product development and manufacturing services. 

Dr. Broudy brings over 20 years of experience in the biopharmaceutical and CDMO. Prior to his appointment, Dr. Broudy served as Chairman of BioCina’s Board of Directors and Operating Partner of Bridgewest Group’s life sciences portfolio. He has been with Bridgewest Group and Bridgewest Group portfolio companies over the past 15 years. Most recently as BioCina’s Chairman of the Board, he has been involved in shaping BioCina’s vision and provided operational leadership to the drug-substance and drug-product businesses. He was Executive Vice President, Corporate Development & Marketing at BioDuro-Sundia, a Bridgewest Group portfolio company, leading the go-to-market strategy for the company. Under the Bridgewest Group umbrella, he previously co-founded and served as CSO of Molecular Response, a specialized contract research organization, which culminated in a strategic acquisition by Crown Bioscience, where he continued as General Manager, where he contributed to a successful initial public offering on the Taipei Exchange. He also previously served as CEO of January Therapeutics, a biotech company focused on nanoparticle formulations. Earlier in his career, he held commercial roles at AltheaDx and Affymetrix, genomics and diagnostics companies. 

Source: BioCina